Eltrombopag free base

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 201240

CAS#: 496775-61-2 (free base)

Description: Eltrombopag is a small-molecule, nonpeptide thrombopoietin receptor agonist with megakaryopoiesis-stimulating activity. Eltrombopag binds to and stimulates the transmembrane domain of the platelet thrombopoietin receptor (TPO-R or CD110), a member of the hematopoietin receptor superfamily. Activation of TPO-R leads to the proliferation and differentiation of cells in the megakaryocytic lineage and an increase in platelet production. Eltrombopag was approved by FDA in November 20, 2008.

Price and Availability

Size Price Shipping out time Quantity
100mg USD 150 Same day
200mg USD 250 Same day
500mg USD 350 Same day
1g USD 550 Same day
2g USD 850 2 weeks
5g USD 1250 2 weeks
10g USD 1950 2 weeks
20g USD 2950 2 weeks
50g USD 3950 2 weeks
Inquire bulk and customized quantity

Pricing updated 2020-08-09. Prices are subject to change without notice.

Eltrombopag free base purity > 98%, is in stock. The same day shipping out after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 201240
Name: Eltrombopag free base
CAS#: 496775-61-2 (free base)
Chemical Formula: C25H22N4O4
Exact Mass: 442.16411
Molecular Weight: 442.47
Elemental Analysis: C, 67.86; H, 5.01; N, 12.66; O, 14.46

Related CAS #: 496775-61-2 (free base)   496775-62-3 (olamine)    

Synonym: SB497115; SB-497115; SB 497115; SB497115GR; Eltrombopag; Brand name: PROMACTA

IUPAC/Chemical Name: 3'-[2-[(2Z)-1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid


InChi Code: InChI=1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,26,30H,1-3H3,(H,32,33)/b27-22-

SMILES Code: O=C(C1=CC(C2=CC=CC(N/N=C3C(C)=NN(C4=CC=C(C)C(C)=C4)C/3=O)=C2O)=CC=C1)O

Technical Data

Red solid powder

>98% (or refer to the Certificate of Analysis)

Safety Data Sheet (SDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Additional Information

Related CAS#
496775-61-2 (Eltrombopag free base);
496775-62-3 (Eltrombopag olamine).


1: Eltrombopag Olamine (Revolade) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug. Available from http://www.ncbi.nlm.nih.gov/books/NBK362529/ PubMed PMID: 27227203.

2: Merli P, Strocchio L, Vinti L, Palumbo G, Locatelli F. Eltrombopag for treatment of thrombocytopenia-associated disorders. Expert Opin Pharmacother. 2015;16(14):2243-56. doi: 10.1517/14656566.2015.1085512. Review. PubMed PMID: 26364898.

3: McCormack PL. Eltrombopag: a review of its use in patients with severe aplastic anaemia. Drugs. 2015 Apr;75(5):525-31. doi: 10.1007/s40265-015-0363-4. Review. PubMed PMID: 25700916.

4: Desmond R, Townsley DM, Dunbar C, Young NS. Eltrombopag in aplastic anemia. Semin Hematol. 2015 Jan;52(1):31-7. doi: 10.1053/j.seminhematol.2014.10.002. Epub 2014 Oct 31. Review. PubMed PMID: 25578417; PubMed Central PMCID: PMC4293077.

5: Burness CB. Eltrombopag: a review of its use in the treatment of thrombocytopenia in patients with chronic hepatitis C. Drugs. 2014 Oct;74(16):1961-71. doi: 10.1007/s40265-014-0312-7. Review. PubMed PMID: 25331767.

6: Mihăilă RG, Cipăian RC. Eltrombopag in chronic hepatitis C. World J Gastroenterol. 2014 Sep 21;20(35):12517-21. doi: 10.3748/wjg.v20.i35.12517. Review. PubMed PMID: 25253952; PubMed Central PMCID: PMC4168085.

7: Pathak S, Roth M, Verma A, Steidl U. Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders. Expert Opin Drug Metab Toxicol. 2013 Dec;9(12):1667-75. doi: 10.1517/17425255.2013.858119. Epub 2013 Nov 12. Review. PubMed PMID: 24215532.

8: Giannini EG, Afdhal NH. Eltrombopag in patients with chronic liver disease. Expert Opin Pharmacother. 2013 Apr;14(5):669-78. doi: 10.1517/14656566.2013.775249. Epub 2013 Mar 4. Review. PubMed PMID: 23452139.

9: Danish FI, Yasmin S. The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia. Hepat Med. 2013 Mar 15;5:17-30. doi: 10.2147/HMER.S27100. eCollection 2013. Review. PubMed PMID: 24696622; PubMed Central PMCID: PMC3953736.

10: Cooper KL, Fitzgerald P, Dillingham K, Helme K, Akehurst R. Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison. Int J Technol Assess Health Care. 2012 Jul;28(3):249-58. doi: 10.1017/S0266462312000414. Review. PubMed PMID: 22980701.

11: Sharma V, Randhawa H, Sharma A, Aggarwal S. Eltrombopag--an oral thrombopoietin agonist. Eur Rev Med Pharmacol Sci. 2012 Jun;16(6):743-6. Review. PubMed PMID: 22913204.

12: Boyers D, Jia X, Crowther M, Jenkinson D, Fraser C, Mowatt G. Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP). Health Technol Assess. 2011 May;15 Suppl 1:23-32. doi: 10.3310/hta15suppl1/03. Review. PubMed PMID: 21609650.

13: Boyers D, Jia X, Jenkinson D, Mowatt G. Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal. Pharmacoeconomics. 2012 Jun 1;30(6):483-95. doi: 10.2165/11591550-000000000-00000. Review. PubMed PMID: 22480381.

14: Zhang Y, Kolesar JM. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura. Clin Ther. 2011 Nov;33(11):1560-76. doi: 10.1016/j.clinthera.2011.10.004. Epub 2011 Nov 4. Review. PubMed PMID: 22054810.

15: Garnock-Jones KP. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia. BioDrugs. 2011 Dec 1;25(6):401-4. doi: 10.2165/11207620-000000000-00000. Review. PubMed PMID: 22050343.

16: Garnock-Jones KP. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia. Drugs. 2011 Jul 9;71(10):1333-53. doi: 10.2165/11207390-000000000-00000. Review. PubMed PMID: 21770480.

17: Nieto M, Calvo G, Hudson I, Feldschreiber P, Brown D, Lee CC, Lay G, Valeri A, Abadie E, Thomas A, Pignatti F. The European Medicines Agency review of eltrombopag (Revolade) for the treatment of adult chronic immune (idiopathic) thrombocytopenic purpura: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Haematologica. 2011 Sep;96(9):e33-40. doi: 10.3324/haematol.2011.048819. Epub 2011 Jun 28. Review. PubMed PMID: 21712542; PubMed Central PMCID: PMC3166089.

18: Bussel JB, Pinheiro MP. Eltrombopag. Cancer Treat Res. 2011;157:289-303. doi: 10.1007/978-1-4419-7073-2_17. Review. PubMed PMID: 21052963.

19: Cook L, Cooper N. Eltrombopag--a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations. Drug Des Devel Ther. 2010 Jul 21;4:139-45. Review. PubMed PMID: 20689640; PubMed Central PMCID: PMC2915538.

20: Chouhan JD, Herrington JD. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag. Pharmacotherapy. 2010 Jul;30(7):666-83. doi: 10.1592/phco.30.7.666. Review. PubMed PMID: 20575632.